<DOC>
	<DOC>NCT00000298</DOC>
	<brief_summary>The purpose of this study is to determine target dose range of buprenorphine/naloxone combination tablet that provides therapeutic response in opiate addicts with low to moderate dependence, and to identify appropriate initial induction dose in opiate addicts with low to moderate dependence."</brief_summary>
	<brief_title>Buprenorphine Combination Tablet Feasibility - 1</brief_title>
	<detailed_description />
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
	<criteria>Males/Females ages 2150, opiate dependence according to DSMIV criteria, selfreported use within the last 30 days, agreeable to conditions of study and signed informed consent Psychiatric disorder that requires medication therapy, history of seizures, pregnant and/or nursing women, dependence on etoh or benzodiazepines or other sedativehypnotics, acute hepatitis, other medical conditions that deem participation to be unsafe.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 1996</verification_date>
</DOC>